This negative impact of breast tumour-associated pDCs (TA-pDCs) on clinical outcomes has been linked to an IFN-α production defect driven by tumour-derived soluble factors, like transforming growth factor-β (TGF-β)44. This evidence concerns the gene IFNA1 and neoplasm.